SOPHiA GENETICS Posts 19% Revenue Growth in 2025, Eyes EBITDA Breakeven by 2026

Event summary

  • SOPHiA GENETICS reported $77.3M in 2025 revenue, up 19% YoY, with Q4 revenue growing 22% YoY.
  • Adjusted gross margin expanded 140 basis points to 74.2% despite a 40% increase in terabytes processed.
  • Signed 124 new core genomic customers in 2025, including two major U.S. health systems expected to add 60,000 analyses annually.
  • Performed over 391,000 analyses in 2025, with 528 core genomics customers as of December 31, 2025.
  • Expects to approach adjusted EBITDA breakeven by the end of 2026 and cross over to positive adjusted EBITDA in the second half of 2027.

The big picture

SOPHiA GENETICS' strong 2025 performance underscores the growing demand for AI-driven precision medicine, particularly in the U.S. market. The company's ability to maintain high gross margins while scaling its platform positions it well amidst increasing competition in the genomic data analysis space. The strategic focus on expanding its Liquid Biopsy and BioPharma applications could further differentiate its offerings in the coming years.

What we're watching

U.S. Market Execution
Whether SOPHiA GENETICS can sustain its 50% YoY U.S. analysis volume growth and capitalize on the two major health system contracts.
Application Expansion
The pace at which the company can scale its Liquid Biopsy and Solid Tumor applications, given the 70+ customers already signed for MSK-ACCESS®.
BioPharma Partnerships
How the recent global commercial agreement with a top 5 oncology-focused pharmaceutical company will impact 2026 growth.